Back to List View Graph View

Imatinib

Imatinib is a small-molecule tyrosine-kinase inhibitor used prominently in the treatment of chronic myeloid leukemia (CML), where it targets the ABL1 kinase activity of the BCR::ABL1 fusion protein.

Where the papers sit

10 papers from the last 6 months study imatinib directly · updated from PubMed 5 Nov 2026

Study type 0 clinical trials · 3 observational · 1 human data · 6 preclinical

Themes 3 themes · 1 paradigm shift

  • Chronic Myeloid Leukemia Care

    Chronic myeloid leukemia care is moving from generic TKI use toward patient-specific selection, safety monitoring and molecular management. Nilotinib and other TKIs are assessed in pediatric and diabetic populations, with early adverse events and arterial stiffness as recurring clinical concerns. Imatinib resistance is linked to the circRNA-CDCA4/AKT axis, while the AKT-mTOR pathway and NCX1 point to additional therapeutic targets. Cohort outcomes and mechanistic studies remain complementary rather than establishing a single preferred regimen.

    5 papers · 50%

  • Experimental Disease Therapies

    Host-directed therapy for tuberculous meningitis appears alongside drug-combination and targeted-treatment experiments in cancer. Icaritin is paired with imatinib to enhance anti-leukemic activity in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Other work tests small molecules in desmoplastic small round cell tumors, with mitochondrial depolarization, Foxo1 and cell death among the mechanistic readouts. No single disease trajectory or shared therapeutic conclusion unites the set.

    3 papers · 30%

  • Cancer Therapy and Vascular Biology

    Ultrasound-triggered PLGA nanoparticles co-loaded with celecoxib and catalase are being used to improve imatinib delivery and efficacy in gastrointestinal stromal tumors. The reported endpoints center on cell viability, growth and apoptosis, with phase-change behavior enabling responsive treatment. A separate study links platelet-derived growth factor to uremic vascular calcification rather than tumor therapy. No common biological question or directional trend unites the cluster.

    2 papers · 20%

PARADIGM SHIFT

Imatinib is shown to act as a host- or tissue-directed treatment beyond malignant-cell targeting

The tuberculous meningitis study using mice, human brain organoids, and patient-derived PBMCs 42481504Jul and the uremic vascular-calcification study using murine aortas and CKD mice 42302932Jun depart from the cancer-centered assumption that imatinib’s therapeutic role is chiefly to inhibit malignant cells. Instead, imatinib reduced neuroinflammation and disease-associated neurological injury in the meningitis models, while inhibiting PDGF signaling reduced vascular calcification in uremic models. Together, these independent disease systems establish a broader role for imatinib as a modulator of pathological host or tissue signaling, not only as an antineoplastic agent.

imatinib chemical structure

Papers

The 10 papers from the last 6 months that study imatinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Chronic Myeloid Leukemia Care (5)
  1. Hsa_circ_0029325 drives imatinib resistance via the CDCA4/AKT axis in chronic myeloid leukemia. Molecular biology reports · 10 Oct 2026 PMID 42859301
  2. Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
  3. Exploring the therapeutic potential of NCX1 in hematological cancers; integration of molecular docking, bioinformatics approaches, and experimental validation. Biochemical and biophysical research communications · 24 Jul 2026 PMID 42497834
  4. Treatment Patterns and Outcomes of Pediatric Chronic Myeloid Leukemia in a Brazilian Multicenter Cohort. Pediatric blood & cancer · 23 Jul 2026 PMID 42489578
  5. Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network. European journal of haematology · 22 Jul 2026 PMID 42486531
Experimental Disease Therapies (3)
  1. Icaritin enhances the anti-leukemic activity of imatinib in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia cells: functional involvement of PI3K/AKT signaling. Hematology (Amsterdam, Netherlands) · 4 Nov 2026 PMID 42981166
  2. Evaluation of novel targeted small-molecule therapeutics in desmoplastic small round cell tumor (DSRCT) cells. Journal of cancer research and clinical oncology · 3 Oct 2026 PMID 42828699
  3. Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models. Nature communications · 21 Jul 2026 PMID 42481504
Cancer Therapy and Vascular Biology (2)
  1. Ultrasound-responsive PLGA nanoparticles co-loaded with celecoxib and catalase enhance the therapeutic efficacy of imatinib in gastrointestinal stromal tumors. International journal of pharmaceutics · 22 Aug 2026 PMID 42632578
  2. The role of platelet-derived growth factor in uremic vascular calcification. Kidney international · 16 Jun 2026 PMID 42302932

By study type

Observational studies and case reports (3)
  1. Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
  2. Treatment Patterns and Outcomes of Pediatric Chronic Myeloid Leukemia in a Brazilian Multicenter Cohort. Pediatric blood & cancer · 23 Jul 2026 PMID 42489578
  3. Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network. European journal of haematology · 22 Jul 2026 PMID 42486531
Human data, design not indexed (1)
  1. Exploring the therapeutic potential of NCX1 in hematological cancers; integration of molecular docking, bioinformatics approaches, and experimental validation. Biochemical and biophysical research communications · 24 Jul 2026 PMID 42497834
Preclinical: animal, cell and lab studies (6)
  1. Icaritin enhances the anti-leukemic activity of imatinib in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia cells: functional involvement of PI3K/AKT signaling. Hematology (Amsterdam, Netherlands) · 4 Nov 2026 PMID 42981166
  2. Hsa_circ_0029325 drives imatinib resistance via the CDCA4/AKT axis in chronic myeloid leukemia. Molecular biology reports · 10 Oct 2026 PMID 42859301
  3. Evaluation of novel targeted small-molecule therapeutics in desmoplastic small round cell tumor (DSRCT) cells. Journal of cancer research and clinical oncology · 3 Oct 2026 PMID 42828699
  4. Ultrasound-responsive PLGA nanoparticles co-loaded with celecoxib and catalase enhance the therapeutic efficacy of imatinib in gastrointestinal stromal tumors. International journal of pharmaceutics · 22 Aug 2026 PMID 42632578
  5. Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models. Nature communications · 21 Jul 2026 PMID 42481504
  6. The role of platelet-derived growth factor in uremic vascular calcification. Kidney international · 16 Jun 2026 PMID 42302932